Show
Sort by
-
Identifying patients with chronic lymphocytic leukemia without need of treatment : end of endless watch and wait?
-
Long-term follow-up, up to 7 years, in the RESONATE-2 study of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL)
(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 21(Supplement 1). p.S316-S316 -
- Journal Article
- A1
- open access
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia : results from the pivotal phase III study COMPLEMENT1
-
- Journal Article
- A1
- open access
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study
-
Five-year follow-up after ibrutinib therapy for first-line treatment of chronic lymphocytic leukemia
-
Effect of dose modifications on response to duvelisib in patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO trial
-
The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
-
The light chain IgLV3-21 defines a new poor prognostic subgroup in chronic lymphocytic leukemia : results of a multicenter study
-
- Journal Article
- A1
- open access
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : extended phase 3 results from RESONATE-2
-
Mimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation